SNY · NASDAQ · STOCK
Sanofi (SNY) Stock Analysis
$40.07
52W $39.18 – $52.68
62/100
$96.22B
21.9
0.30
Is SNY Bullish or Bearish?
Bullish.
Innellis AI committee rates Sanofi (SNY) Buy with a composite score of 62/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +13.42 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -6.58 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.28) -- balance sheet can absorb a shock. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- Dividend yield of 4.1% pays you to wait — Value
- 4 consecutive earnings beats -- consistent execution — Growth
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.28) -- balance sheet can absorb a shock — Risk
Bear Case
- EPS declining -55.6% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price structure (HH_HL) contradicts the downtrend -- mixed signals — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
62/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 24%
of 192 Healthcare peers
Value Analyst
bullish
70
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ Price-to-book of 1.4x is a discount to asset value
Growth Analyst
neutral
50
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 4 consecutive earnings beats -- consistent execution
− EPS declining -55.6% YoY despite any revenue growth
Technical Analyst
neutral
47
/ 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement
− Price structure making lower highs and lower lows
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.28) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 61.6 to 61.6.
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
35.3
Neutral
MACD Histogram
-0.052
Bearish Momentum
Trend Direction
Downtrend
Weekly: Downtrend
Market Structure
Hh Hl
Bollinger %B
0.25
Inside Bands
Price vs Moving Averages
EMA 9
$40.35
Below
EMA 21
$41.23
Below
EMA 50
$42.38
Below
EMA 200
$44.73
Below
Fundamental Analysis
Valuation
91
Growth
67
Profitability
64
Financial Health
58
Cash Flow
70
Valuation
P/E Ratio
21.9×
P/B Ratio
1.24×
PEG Ratio
-0.39
Dividend Yield
11.65%
52W High
$52.68
52W Low
$39.18
Quality & Growth
ROE
1094.6%
ROA
616.1%
Gross Margin
7276.5%
Operating Margin
2058.1%
Revenue Growth YoY
—
Debt / Equity
0.34
AI Fundamental Assessment
P/E ratio of 21.9 (inexpensive relative to a 15-40x range); Price-to-book of 1.2x; PEG ratio of -0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 10.9%; Return on assets of 6.2%; Net margin of 8.1%; Gross margin of 72.8%; Current ratio of 0.99 (tight short-term liquidity); Debt-to-equity of 0.34; Free cash flow per share is positive (6.89); Most recent quarter beat estimates by 8.9%; 4 consecutive earnings beats; EPS growth decelerating (+22.9% -> +11.2% QoQ); Analyst estimates rising over recent quarters
Get the Full SNY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →